Skip to content

The value of high frame rate contrast-enhanced ultrasound in the differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma and the predictive performance of microvascular invasion

The value of high frame rate contrast-enhanced ultrasound in the differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma and the predictive performance of microvascular invasion

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058927
Enrollment
Unknown
Registered
2022-04-20
Start date
2022-04-20
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver lesions

Interventions

Gold Standard:pathological diagnosis
Index test:contrast-enhanced ultrasound examination in liver

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Suspected hepatic malignant space-occupying lesions with a size of 1-5cm; 2. Liver nodules did not receive any related treatment; 3. No puncture pathological biopsy was performed on the lesion before angiography; 4. Puncture pathology or surgical pathology were found in the lesions after angiography.

Exclusion criteria

Exclusion criteria: 1. Incomplete clinical data; 2. There was no enhancement in the third stage of the lesion after angiography; 3. Preoperative anticancer therapy was performed before CEUS; 4. History of adverse reactions with sulfur hexafluoride or phospholipids; 5. Patients with history of asthma, urticaria, malignant tumor and other cachexia.

Design outcomes

Primary

MeasureTime frame
imaging index;

Countries

China

Contacts

Public ContactZhang Bo

Xiangya Hospital of Central South University

zhangbo8095@126.com+86 13975888095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026